UroGen Pharma to Present at Upcoming Investor Conferences

Company Overview - UroGen Pharma Ltd. is a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty cancers, aiming to provide better treatment options for patients [3] - The company has developed RTGel®, a proprietary sustained-release hydrogel-based platform technology that enhances the therapeutic profiles of existing drugs, allowing for longer exposure of urinary tract tissue to medications [3] - UroGen's first product is approved for treating low-grade upper tract urothelial cancer, while its second product is the first and only FDA-approved medication for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, both designed for non-surgical tumor ablation [3] Upcoming Investor Conferences - UroGen will participate in the Wells Fargo Healthcare Conference on September 3rd at 2:15 PM ET in Boston, MA, in a fireside chat format [2] - The company will also attend the Cantor Fitzgerald Global Healthcare Conference on September 4th at 3:55 PM ET in New York, NY, also in a fireside chat format [2] - Additionally, UroGen will be present at the H.C. Wainwright 27th Annual Global Healthcare Conference on September 8th at 9:00 AM ET in New York, NY, in a fireside chat format [2]